

ChemoCentryx, Inc.
Form 4
July 13, 2017

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Bekker Petrus

(Last) (First) (Middle)

C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE

(Street)

MOUNTAIN VIEW, CA 94043

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ChemoCentryx, Inc. [CCXI]

3. Date of Earliest Transaction (Month/Day/Year)
07/11/2017

4. If Amendment, Date Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V Amount (A) or (D) Price			
Common Stock	07/11/2017		M	6,124 A \$ 6.3	65,963	D	
Common Stock	07/11/2017		S ⁽¹⁾	6,124 D \$ 9.3	59,839	D	
Common Stock	07/11/2017		M	23,876 A \$ 6.9	83,715	D	
Common Stock	07/11/2017		S ⁽¹⁾	23,876 D \$ 9.9	59,839	D	
Common Stock	07/12/2017		M	10,000 A \$ 6	69,839	D	

Edgar Filing: ChemoCentryx, Inc. - Form 4

Common Stock	07/12/2017	S ⁽¹⁾	10,000	D	\$ 10	59,839	D
Common Stock	07/12/2017	M	1,250	A	\$ 6.3	61,089	D
Common Stock	07/12/2017	S ⁽¹⁾	1,250	D	\$ 10	59,839	D
Common Stock	07/12/2017	M	9,253	A	\$ 6.9	69,092	D
Common Stock	07/12/2017	S ⁽¹⁾	9,253	D	\$ 9.9222 ⁽²⁾	59,839	D
Common Stock	07/12/2017	M	6,997	A	\$ 7.1	66,836	D
Common Stock	07/12/2017	S ⁽¹⁾	6,997	D	\$ 10	59,839	D
Common Stock	07/12/2017	M	2,500	A	\$ 8.19	62,339	D
Common Stock	07/12/2017	S ⁽¹⁾	2,500	D	\$ 10	59,839	D
Common Stock	07/13/2017	M	3,888	A	\$ 7.1	63,727	D
Common Stock	07/13/2017	S ⁽¹⁾	3,888	D	\$ 10.28	59,839	D
Common Stock	07/13/2017	M	12,125	A	\$ 8.19	71,964	D
Common Stock	07/13/2017	S	12,125	D	\$ 10.1852 ⁽³⁾	59,839	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. D S (1)
--	--	--------------------------------------	--	--------------------------------	---	--	---	------------

Edgar Filing: ChemoCentryx, Inc. - Form 4

			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 6.3	07/11/2017	M			6,124	<u>(4)</u>	08/10/2020	Common Stock	6,124
Stock Option (right to buy)	\$ 6.9	07/11/2017	M			23,876	<u>(4)</u>	08/04/2021	Common Stock	23,876
Stock Option (right to buy)	\$ 6	07/12/2017	M			10,000	<u>(4)</u>	02/17/2019	Common Stock	10,000
Stock Option (right to buy)	\$ 6.3	07/12/2017	M			1,250	<u>(4)</u>	08/10/2020	Common Stock	1,250
Stock Option (right to buy)	\$ 6.9	07/12/2017	M			9,253	<u>(4)</u>	08/04/2021	Common Stock	9,253
Stock Option (right to buy)	\$ 7.1	07/12/2017	M			6,997	<u>(4)</u>	02/19/2024	Common Stock	6,997
Stock Option (right to buy)	\$ 8.19	07/12/2017	M			2,500	<u>(4)</u>	02/23/2025	Common Stock	2,500
Stock Option (right to buy)	\$ 7.1	07/13/2017	M			3,888	<u>(4)</u>	02/19/2024	Common Stock	3,888
Stock Option (right to buy)	\$ 8.19	07/13/2017	M			12,125	<u>(4)</u>	02/23/2025	Common Stock	12,125

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other

Bekker Petrus
C/O CHEMOCENTRYX, INC.
850 MAUDE AVENUE
MOUNTAIN VIEW, CA 94043

Chief Medical Officer

Signatures

Susan M. Kanaya, as
Attorney-in-Fact

07/13/2017

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Reflects the weighted average sale price of the shares purchased. The shares were purchased in multiple trades at prices ranging from

(2) \$9.90 to \$10.00 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.

Reflects the weighted average sale price of the shares purchased. The shares were purchased in multiple trades at prices ranging from

(3) \$10.00 to \$10.37 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.

(4) As of July 11, 2017, and prior to this transaction, the exercised options were fully vested.

(5) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.